Estrogen Metabolite 2-Methoxyestradiol Induces Apoptosis and Inhibits Cell Proliferation and Collagen Production in Rat and Human Leiomyoma Cells: A Potential Medicinal Treatment for Uterine Fibroids

Journal of the Society for Gynecologic Investigation

Volumn 13, Issue 8, 2006, Pages 542-550

  Salama, Salama A ^a   Nasr, Abdelhakim Ben ^a   Dubey, Raghvendra K ^b   Al Hendy, Ayman ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

2 Methoxyestradiol; apoptosis; cell cycle; collagen synthesis; uterine leiomyoma

Indexed keywords

2 METHOXYESTRADIOL; COLLAGEN; CYCLIN D1; ESTROGEN; PROLINE; PROTEIN BAX; PROTEIN BCL 2; THYMIDINE; TRITIUM; VASCULOTROPIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEIOMYOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UTERUS MYOMA; WESTERN BLOTTING;

ANIMALS; ANTIMITOTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLLAGEN; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; LEIOMYOMA; RATS; UTERINE NEOPLASMS;

EID: 33845433205     PISSN: 10715576     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsgi.2006.09.003     Document Type: Article

References (50)

1. Al-Hendy A., Lee E.J., Wang H.Q., and Copland J.A. Gene therapy of uterine leiomyomas: Adenovirus-mediated expression of dominant negative estrogen receptor inhibits tumor growth in nude mice. Am J Obstet Gynecol 191 (2004) 1621-1631
2. Walker C.L., and Stewart E.A. Uterine fibroids: The elephant in the room. Science 308 (2005) 1589-1592
3. Cook J.D., Davis B.J., Cai S.L., et al. Interaction between genetic susceptibility and early-life environmental exposure determines tumor-suppressor-gene penetrance. Proc Natl Acad Sci U S A 102 (2005) 8644-8649
4. Maruo T., Ohara N., Wang J., and Matsuo H. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update 10 (2004) 207-220
5. Cook J.D., and Walker C.L. Treatment strategies for uterine leiomyoma: The role of hormonal modulation. Semin Reprod Med 22 (2004) 105-111
6. Martel K.M., Ko A.C., Christman G.M., and Stribley J.M. Apoptosis in human uterine leiomyomas. Semin Reprod Med 22 (2004) 91-103
7. Strober S., Lowsky R.J., Shizuru J.A., Scandling J.D., and Millan M.T. Approaches to transplantation tolerance in humans. Transplantation 77 (2004) 932-936
8. Ishwad C.S., Ferrell R.E., Davare J., et al. Molecular and cytogenetic analysis of chromosome 7 in uterine leiomyomas. Genes Chromosomes Cancer 14 (1995) 51-55
9. Bodner K., Bodner-Adler B., Kimberger O., Czerwenka K., and Mayerhofer K. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: An immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma. J Soc Gynecol Investig 11 (2004) 187-191
10. Matsuo H. Molecular bases for the actions of ovarian sex steroids in the regulation of proliferation and apoptosis of human uterine leiomyoma. Oncology 57 (1999) 49-58
11. Zhao J., Dorland M., Taverne M.A., et al. In vitro culture of rat pre-antral follicles with emphasis on follicular interactions. Mol Reprod Dev 55 (2000) 65-74
12. Kawaguchi K., Fujii S., Konishi I., Okamura H., and Mori T. Ultrastructural study of cultured smooth muscle cells from uterine leiomyoma and myometrium under the influence of sex steroids. Gynecol Oncol 21 (1985) 32-41
13. Stewart E.A., Friedman A.J., Peck K., and Nowak R.A. Relative overexpression of collagen type I and collagen type III messenger ribonucleic acids by uterine leiomyomas during the proliferative phase of the menstrual cycle. J Clin Endocrinol Metab 79 (1994) 900-906
14. Zhu B.T., and Conney A.H. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis?. Cancer Res 58 (1998) 2269-2277
15. Lis A., Ciesielski M.J., Barone T.A., et al. 2-Methoxyestradiol inhibits proliferation of normal and neoplastic glial cells, and induces cell death, in vitro. Cancer Lett 213 (2004) 57-65
16. Joubert A., Maritz C., and Joubert F. Bax/Bcl-2 expression levels of 2-methoxyestradiol-exposed esophageal cancer cells. Biomed Res 26 (2005) 131-134
17. Chamaon K., Stojek J., Kanakis D., et al. Micromolar concentrations of 2-methoxyestradiol kill glioma cells by an apoptotic mechanism, without destroying their microtubule cytoskeleton. J Neurooncol 72 (2005) 11-16
18. Bu S.Z., Huang Q., Jiang Y.M., et al. p38 Mitogen-activated protein kinases is required for counteraction of 2-methoxyestradiol to estradiol-stimulated cell proliferation and induction of apoptosis in ovarian carcinoma cells via phosphorylation Bcl-2. Apoptosis 11 (2006) 413-425
19. Zacharia L.C., Gogos J.A., Karayiorgou M., et al. Methoxyestradiols mediate the antimitogenic effects of 17beta-estradiol: Direct evidence from catechol-O-methyltransferase-knockout mice. Circulation 108 (2003) 2974-2978
20. Banerjee S.N., Sengupta K., Banerjee S., Saxena N.K., and Banerjee S.K. 2-Methoxyestradiol exhibits a biphasic effect on VEGF-A in tumor cells and upregulation is mediated through ER-alpha: A possible signaling pathway associated with the impact of 2-ME2 on proliferative cells. Neoplasia 5 (2003) 417-426
21. Dubey R.K., Jackson E.K., Gillespie D.G., et al. Clinically used estrogens differentially inhibit human aortic smooth muscle cell growth and mitogen-activated protein kinase activity. Arterioscler Thromb Vasc Biol 20 (2000) 964-972
22. Mooberry S.L. New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Curr Opin Oncol 15 (2003) 425-430
23. Lakhani N.J., Sarkar M.A., Venitz J., and Figg W.D. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 23 (2003) 165-172
24. Sweeney C., Liu G., Yiannoutsos C., et al. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res 11 (2005) 6625-6633
25. Howe S.R., Gottardis M.M., Everitt J.I., et al. Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. Am J Pathol 146 (1995) 1568-1579
26. Rauk P.N., Surti U., Roberts J.M., and Michalopoulos G. Mitogenic effect of basic fibroblast growth factor and estradiol on cultured human myometrial and leiomyoma cells. Am J Obstet Gynecol 173 (1995) 571-577
27. Swartz C.D., Afshari C.A., Yu L., Hall K.E., and Dixon D. Estrogen-induced changes in IGF-I, Myb family and MAP kinase pathway genes in human uterine leiomyoma and normal uterine smooth muscle cell lines. Mol Hum Reprod 11 (2005) 441-450
28. Teare J.M., Islam R., Flanagan R., et al. Measurement of nucleic acid concentrations using the DyNA Quant and the GeneQuant. Biotechniques 22 (1997) 1170-1174
29. Telford W.G., King L.E., and Fraker P.J. Rapid quantitation of apoptosis in pure and heterogeneous cell populations using flow cytometry. J Immunol Methods 172 (1994) 1-16
30. Vijayanathan V., Venkiteswaran S., Nair S.K., et al. Physiologic levels of 2-methoxyestradiol interfere with nongenomic signaling of 17beta-estradiol in human breast cancer cells. Clin Cancer Res 12 (2006) 2038-2048
31. Schumacher G., and Neuhaus P. [2-Methoxyestradiol-A new compound for cancer treatment]. Dtsch Med Wochenschr 131 (2006) 825-830
32. Figg W.D., Kruger E.A., Price D.K., Kim S., and Dahut W.D. Inhibition of angiogenesis: Treatment options for patients with metastatic prostate cancer. Invest New Drugs 20 (2002) 183-194
33. Mabjeesh N.J., Escuin D., LaVallee T.M., et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3 (2003) 363-375
34. Gokmen-Polar Y., Escuin D., Walls C.D., et al. beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells. Cancer Res 65 (2005) 9406-9414
35. Qadan L.R., Perez-Stable C.M., Anderson C., et al. 2-Methoxyestradiol induces G2/M arrest and apoptosis in prostate cancer. Biochem Biophys Res Commun 285 (2001) 1259-1266
36. Barchiesi F., Jackson E.K., Gillespie D.G., et al. Methoxyestradiols mediate estradiol-induced antimitogenesis in human aortic SMCs. Hypertension 39 (2002) 874-879
37. Lewis J.S., Thomas T.J., Pestell R.G., et al. Differential effects of 16alpha-hydroxyestrone and 2-methoxyestradiol on cyclin D1 involving the transcription factor ATF-2 in MCF-7 breast cancer cells. J Mol Endocrinol 34 (2005) 91-105
38. Ghosh R., Ott A.M., Seetharam D., Slaga T.J., and Kumar A.P. Cell cycle block and apoptosis induction in a human melanoma cell line following treatment with 2-methoxyoestradiol: Therapeutic implications?. Melanoma Res 13 (2003) 119-127
39. Wyllie A.H., Kerr J.F., and Currie A.R. Cell death: The significance of apoptosis. Int Rev Cytol 68 (1980) 251-306
40. Reed J.C., Talwar H.S., Cuddy M., et al. Mitochondrial protein p26 BCL2 reduces growth factor requirements of NIH3T3 fibroblasts. Exp Cell Res 195 (1991) 277-283
41. Nunez G., London L., Hockenbery D., et al. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 144 (1990) 3602-3610
42. Zhai Y.L., Nikaido T., Toki T., et al. Prognostic significance of bcl-2 expression in leiomyosarcoma of the uterus. Br J Cancer 80 (1999) 1658-1664
43. Matsuo H., Maruo T., and Samoto T. Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab 82 (1997) 293-299
44. Khurana K.K., Singh S.B., Tatum A.H., Schulz V., and Badawy S.Z. Maintenance of increased Bcl-2 expression in uterine leiomyomas after GnRH agonist therapy. J Reprod Med 44 (1999) 487-492
45. Di Lieto A., De Falco M., Pollio F., et al. Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas. J Soc Gynecol Investig 12 (2005) 123-128
46. Folkman J., and Shing Y. Angiogenesis. J Biol Chem 267 (1992) 10931-10934
47. Gentry C.C., Okolo S.O., Fong L.F., et al. Quantification of vascular endothelial growth factor-A in leiomyomas and adjacent myometrium. Clin Sci (Lond) 101 (2001) 691-695
48. Chauhan D., Catley L., Hideshima T., et al. 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood 100 (2002) 2187-2194
49. Ferenczy A., Richart R.M., and Okagaki T. A comparative ultrastuctural study of leiomyosarcoma, cellular leiomyoma, and leiomyoma of the uterus. Cancer 28 (1971) 1004-1018
50. Purohit A., Tutill H.J., Day J.M., et al. The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer. Molecular Cell Endocrinology 248 (2006) 199-203